1Shaw J E,Sicree R A, Zimmet P Z. Global estimates of the prevalence of diabetes for 2010 and 2030[J]. Diabe- tes Res Clin Pract,2010,87:4-14.
2Nauck M A,Baller B,Meier J J. Gastric inhibitory poly- peptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes [J]. Diabetes, 2004, 53 (Suppl 3 ) : S190-S196.
3Vilsboll T, Holst J J. Incretins, insulin secretion and type 2 diabetes mellitus[J]. Diabetologia, 2004,47 : 357- 366.
4Hinnen D, Nielsen L L, Waninger A, Kushner P. Incre- tin mimetics and DPP-IV inhibitors., new paradigms for the treatment of type 2 diabetes[J]. J Am Board Faro Med, 2006,19: 612-620.
5Green B D, Lavery K S, Irwin N, Oharte F P, Harriott P,Greer B, et al. Novel glucagon-like peptide-1 (GLP- 1) analog (Val8) GLP-1 results in significant improve- ments of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese dia- betic (ob/ob) mice[J]. J Pharmacol Exp Ther, 2006, 318:914-921.
6Zander M, Madsbad S,Madsen J L, Holst J J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study [J]. Lancet, 2002, 359:824-830.
7Monami M, Marchionni M, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes:a meta-a- nalysis of randomized clinical trials[J]. Eur J Endocri- noi,2009,160 : 909-917.
8Astrup A, Rssner S, Van Gaa L, Rissanen A, Nis- kanen L,A1 Hakim M,et al. Effects of liraglutide in the treatment of obesity., a randomised, double-blind, place- bo-controlled study[J].Lancet, 2009,374 :1606-1616.
9Drucker D J,Sherman S I,Gorelick F S, Bergenstal R M,Sherwin R S, Buse J B. Incretin-based therapies for the treatment of type 2 diabetes :evaluation of the risks and benefits[J]. Diabetes Care, 2010,33 : 428-433.
